Table 1.
Some of the repurposed drugs used in breast cancer treatment and the associated biomarkers and the predictive response [29,31,33].
| Drug | Biomarkers | Reported Outcomes |
|---|---|---|
| Doxorubicin | CREB3L1 | Tumour sensitivity; |
| HLA region | Cardiotoxicity predisposition. | |
| Cyclophosphamide | CYP2B6 and CYP2C19 | Drug metabolic rate. |
| Everolimus | CYP3A4 | Higher plasma concentration of everolimus. |
| ABCB1 | ||
| PI3KR1 | Adverse Side Effects | |
| RAPTOR | ||
| Tamoxifen | CYP2D6 | Metabolic rate; |
| CYP19A1 | Effectiveness of the drug. | |
| Anastrozole | CSMD1 | Increased anastrozole sensitivity; |
| CYP19A1 | Drug response. | |
| Paclitaxel | SNPs on LPHN2, ROBO1, SNTG1 and GRIK1 | Insensitivity to drug;bad prognosis |
| Aspirin | PIK3CA mutation | Drug Efficacy |